pmmr

Skip to content The CRC Digest Immunotherapy combinations tested in pMMR/MSS rectal cancer Meta-analysis evaluates immune checkpoint inhibitor-based neoadjuvant therapy for proficient mismatch repair and microsatellite stable locally advanced rectal tumors. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist

Skip to content The CRC Digest ◆ TRIAL DATA Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype A new meta-analysis examined immune checkpoint inhibitor combinations as neoadjuvant therapy for locally advanced rectal cancer with proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors—a subtype that typically does not